Treatment of chronic hepatitis B: options, monitoring, special cases and adverse effects
DOI:
https://doi.org/10.12775/JEHS.2025.77.57419Keywords
hepatitis, hepatitis B, hepatitis B treatment, hepatitis B treatment side effects, hepatitis b monitoring therapy, hepatitis b special casesAbstract
Introduction:
Hepatitis B remains a significant clinical issue. Despite the availability of effective vaccines, the world is still not free from this problem. Chronic hepatitis B virus (HBV) infection affects approximately 296 million people worldwide and is the leading cause of cirrhosis and liver cancer globally. HBV-related cirrhosis resulted in an estimated 331,000 deaths in 2019, and it is estimated that the number of deaths from HBV-related liver cancer in 2019 was 192,000, an increase from 156,000 in 2010. The rate of vaccination is particularly unsatisfactory in low-income countries, but even in high-income countries, the issue of hepatitis B has not been completely eradicated.
Aim of the study: The aim of this paper is primarily to systematize knowledge regarding the natural course of HBV infection and therapeutic options for chronic hepatitis B, both in adults and children. It also aims to highlight the principles of monitoring pharmacotherapy. The paper also describes therapeutic possibilities in special cases, such as pregnancy, liver transplantation, and the initiation of immunosuppressive therapy. Attention is also given to the potential adverse effects of pharmacotherapy.
Conclusions:
As hepatitis B infection continues to pose a significant global health challenge and remains the leading cause of liver cirrhosis and hepatocellular carcinoma, it is essential to review the available treatment options for this condition. Even in Europe, where vaccination coverage has reached high levels, cases of hepatitis B are still detected, often incidentally. This review aims to provide an in-depth analysis of therapeutic approaches for chronic hepatitis B, considering factors such as patient age, clinical status, and liver fibrosis stage. Additionally, it emphasizes the importance of monitoring treatment efficacy and safety, while also addressing the potential adverse effects associated with antiviral therapy.
References
[1] Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA. 2018;319(17):1802–1813. doi:10.1001/jama.2018.3795
[2] Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol. 2012 Mar 27;4(3):74-80. doi: 10.4254/wjh.v4.i3.74
[3] Wilkins T, Sams R, Carpenter M. Hepatitis B: Screening, Prevention, Diagnosis, and Treatment. Am Fam Physician. 2019 Mar 1;99(5):314-323. PMID: 30811163.
[4] Interna Szczeklika 2021. / [red.prow.] Piotr Gajewski Kraków : Wydawnictwo Medycyna Praktyczna, 2021 1-3000 Available from: https://www.mp.pl/ksiegarnia/produkt/20804
[5] Bertoletti A, Kennedy PT. The immune tolerant phase of chronic HBV infection: new perspectives on an old concept. Cell Mol Immunol 2015; 12: 258-63
[6] Jaroszewicz J, Pawłowska M, Tomasiewicz K, et al. Genotype A HBV-persistent infection is associated with high serum HBsAg concentration in treatment naïve patients. Hepatology 2014; 60 Suppl. 1: 1692
[7] Nassal MHBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis BGut 2015;64:1972-1984
[8] Lee, Hye Won, Jae Seung Lee, and Sang Hoon Ahn. 2021. "Hepatitis B Virus Cure: Targets and Future Therapies" International Journal of Molecular Sciences 22, no. 1: 213. doi:10.3390/ijms22010213
[9] Tillmann, H. L., & Samuel, G. (2019). Current state-of-the-art pharmacotherapy for the management of hepatitis B infection. Expert Opinion on Pharmacotherapy, 20(7), 873–885. doi:10.1080/14656566.2019.1583744
[10] Chen, Y. C., & Liaw, Y. F. (2015). Pharmacotherapeutic options for hepatitis B. Expert Opinion on Pharmacotherapy, 17(3), 355–367 doi:10.1517/14656566.2016.1118056
[11] Świderska M, Pawłowska M, Mazur W, et al. Original article Distribution of HBV genotypes in Poland. Clinical and Experimental Hepatology. 2015;1(1):1-4. doi:10.5114/ceh.2015.51372.
[12] Flisiak, Robert, et al. "Zalecenia Polskiej Grupy Ekspertów HBV dotyczące leczenia przewlekłego wirusowego zapalenia wątroby typu B w 2018 roku." Hepatologia 18 (2018): 10-21.
[13] Terrault, N.A., Lok, A.S.F., McMahon, B.J., Chang, K.-M., Hwang, J.P., Jonas, M.M., Brown, R.S., Jr., Bzowej, N.H. and Wong, J.B. (2018), Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 67: 1560-1599. doi:10.1002/hep.29800
[14] Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020 Oct;26(4):411-429. doi: 10.3350/cmh.2020.0049. Epub 2020 Aug 28. PMID: 32854458; PMCID: PMC7641563.
[15] EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2017; 67: 370-98.
[16] Terrault NA, Bzowej NH, Chang KM, et al. American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261-83
[17] Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci 2015; 60: 1457-64
[18] Zoulim F, Białkowska-Warzecha J, Diculescu MM, et al. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. Hepatol Int 2016; 10: 779-88
[19] Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patients selection and therapeutic options. Hepatology 2010; 52: 2192-205
[20] Pawłowska M, Halota W, Kozielewicz D, et al. Virological response to treatment with peginterferon alfa-2a in adolescents with chronic hepatitis B. Acta Biochim Pol 2012; 59: 587-91
[21] Pawłowska M, Halota W, Smukalska E, et al. HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. Eur J Clin Microbiol Infect Dis 2012; 31: 571-4
[22] Murray KF, Szenborn L, Wysocki J, et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56: 2018-26
[23] Jonas MM, Chang MH, Sokal E, et al. Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. Hepatology 2016; 63: 377-87
[24] Ju Hyun Shim, Han Chu Lee, Kang Mo Kim, Young-Suk Lim, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh, Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis, Journal of Hepatology, Volume 52, Issue 2, 2010, Pages 176-182, ISSN 0168-8278, doi:10.1016/j.jhep.2009.11.007
[25] Giles, Michelle L. MBBS, FRACP, PhD; Visvanathan, Kumar MBBS, FRACP, PhD; Lewin, Sharon R. MBBS, FRACP, PhD; Sasadeusz, Joe MBBS, FRACP, PhD‖, Chronic Hepatitis B Infection and Pregnancy. Obstetrical & Gynecological Survey 67(1):p 37-44, January 2012. | DOI: 10.1097/OGX.0b013e31823e464b
[26] Pan CQ, Duan Z, Dai E, et al. China study group for the motherto-child transmission of hepatitis B, tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 2016; 374: 2324-34
[27] Yogeswaran K, Fung SK. Chronic hepatitis B in pregnancy: unique challenges and opportunities. Korean J Hepatol. 2011 Mar;17(1):1-8. doi: 10.3350/kjhep.2011.17.1.1. PMID: 21494071; PMCID: PMC3304622
[28] Jimenez-Perez M, González-Grande R, Mostazo Torres J, et al. Management of hepatitis B virus infection after liver transplantation. World J Gastroenterol 2015; 21: 12083-90
[29] Roche B, Roque-Afonso AM, Nevens F, et al. Rational basis for optimizing short and long-term hepatitis B virus prophylaxis post liver transplantation: role of hepatitis B immune globulin. Transplantation 2015; 99: 1321-34
[30] Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies and future directions. Gastroenterology 2017; 152: 1297-309
[31] Tavakolpour S, Alavian SM, Sali S. Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention: a comprehensive reviewscreened. Hepat Mon 2016; 16: e35810
[32] Perrillo, Robert. "Benefits and risks of interferon therapy for hepatitis B." Hepatology 49.S5 (2009): S103-S111
[33] Viganò, Mauro, et al. "Treatment of hepatitis B: Is there still a role for interferon?." Liver International 38 (2018): 79-83.
[34] Harry L.A. Janssen, Johannes T. Brouwer, Rose C. van der Mast, Solko W. Schalm,
Suicide associated with alfa-interferon therapy for chronic viral hepatitis, Journal of Hepatology, Volume 21, Issue 2, 1994, Pages 241-243, ISSN 0168-8278, doi:10.1016/S0168-8278(05)80402-7
[35] Myrela O. Machado, Giovanni Oriolo, Beatrice Bortolato, Cristiano A. Köhler, Michael Maes, Marco Solmi, Iria Grande, Rocío Martín-Santos, Eduard Vieta, André F. Carvalho,
Biological mechanisms of depression following treatment with interferon for chronic hepatitis C: A critical systematic review, Journal of Affective Disorders, Volume 209, 2017, Pages 235-245, ISSN 0165-0327, doi:10.1016/j.jad.2016.11.039
[36] J. Koskinas, P. Merkouraki, E. Manesis, S. Hadziyannis; Assessment of Depression in Patients with Chronic Viral Hepatitis: Effect of Interferon Treatment. Dig Dis 3 July 2002; 20 (3-4): 284–288. doi:10.1159/000067682
[37] Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol. 2017 Feb 18;9(5):227-241. doi: 10.4254/wjh.v9.i5.227. PMID: 28261380; PMCID: PMC5316843.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Mateusz Litwin, Agnieszka Mikosińska, Jakub Parys, Patrycja Kałuziak, Aleksandra Witek, Martyna Kaźmierczak, Stanisław Jesionek, Marta Jajczak, Maciej Mossakowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 68
Number of citations: 0
